[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Onconetix Inc (ONCO)

Onconetix Inc (ONCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Realbotix Reports Financial Results for Q3-2026

Realbotix Corp . (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leader in humanoid robotics and embodied AI, reports its interim financial results for the...

XBOTF : 0.2050 (-5.49%)
XBOT.VN : 0.290 (unch)
ONCO : 0.8824 (-1.03%)
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series

Entertainment Industry Agreement Reflects Real-World Adoption of Humanoid Robotics Technology Across Education, Healthcare, Hospitality, and Customer Engagement; Onconetix Recently Entered into a Definitive...

ONCO : 0.8824 (-1.03%)
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG

Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company’s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE)...

ONCO : 0.8824 (-1.03%)
Realbotix Corp. Provides Corporate Structure and Operations Update

Commercial robotics and online consumer businesses maintain separate management, personnel, operations and product strategies

XBOTF : 0.2050 (-5.49%)
XBOT.VN : 0.290 (unch)
ONCO : 0.8824 (-1.03%)
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom’s...

ONCO : 0.8824 (-1.03%)
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District

Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix...

ONCO : 0.8824 (-1.03%)
Realbotix Reports Financial Results for Q2-2026

Realbotix Corp . (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leading developer of humanoid robots and AI systems designed for human interaction across...

XBOTF : 0.2050 (-5.49%)
XBOT.VN : 0.290 (unch)
ONCO : 0.8824 (-1.03%)
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split

CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development,...

ONCO : 0.8824 (-1.03%)
Realbotix Provides Update on Nasdaq Listing

Transaction to take Realbotix LLC, a premier social humanoid robot company, to the Nasdaq

XBOTF : 0.2050 (-5.49%)
XBOT.VN : 0.290 (unch)
ONCO : 0.8824 (-1.03%)
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study

New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances...

ONCO : 0.8824 (-1.03%)

Barchart Exclusives

H&R Block Posted Strong Earnings and Boosted Its Dividend by Nearly 10%. What This Means for HRB Stock.
H&R Block beat fiscal fourth-quarter estimates, raised its fiscal 2027 outlook, and increased its quarterly dividend by nearly 10% to $0.46 per share, sending the stock up about 16%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.